When a new medicine hits the market, no one knows all its risks. Even after years of clinical trials, rare side effects only show up once millions of people start using it. That’s where drug safety monitoring comes in - a global network quietly watching for hidden dangers in medicines we take every day. It’s not glamorous, but it saves lives.
How the Global System Works
The backbone of international drug safety monitoring is the WHO Programme for International Drug Monitoring (PIDM), launched in 1968. It’s run by the Uppsala Monitoring Centre (UMC) in Sweden and relies on a single, massive database called VigiBase. As of 2023, VigiBase holds over 35 million Individual Case Safety Reports (ICSRs) from more than 170 countries. Each report is a real-world story: a patient took a drug, had an unexpected reaction, and someone - a doctor, pharmacist, or even the patient - reported it.
These reports don’t come in random formats. They follow strict standards. The ICSRs are sent using the E2B(R3) electronic format, which makes sure every detail - from the drug name and dose to the patient’s age and symptoms - is recorded the same way everywhere. The drugs themselves are matched against WHODrug Global, a dictionary with over 300,000 medicine names. Symptoms are coded using MedDRA, a medical terminology system with 78,000+ standardized terms. This uniformity is what lets computers scan millions of reports and spot patterns that humans would miss.
Who Reports and How?
Every country with a national pharmacovigilance center contributes to this system. But not all systems are equal. In high-income countries like Sweden, Australia, or the UK, reporting is built into daily healthcare. The UK’s Yellow Card Scheme gets over 100,000 reports a year, with 78% of healthcare workers using a mobile app to submit them within 48 hours. In contrast, in many low-income countries, reporting is still paper-based, delayed, or nonexistent.
The biggest gap? Data. Countries with 16% of the world’s population - mostly high-income - send 85% of all reports to VigiBase. Sweden reports 1,200 adverse events per 100,000 people annually. Nigeria? Just 2.3 per 100,000. That doesn’t mean Nigerians have safer drugs. It means they’re not reporting. Without data, signals go unseen.
Regional Systems: EU, US, and WHO
The European Union runs EudraVigilance, a separate but powerful system. It handles about 1.2 million new reports each year, with 98% submitted electronically within 7 days. Unlike WHO, the EU has legal teeth: drug companies must report adverse events within 15 days of learning about them. The EU’s Pharmacovigilance Risk Assessment Committee (PRAC) reviews urgent signals in 60 days - far faster than the global average of 120.
The U.S. FDA’s FAERS system gets around 2 million reports a year. But it operates independently. While the FDA does send some data to VigiBase, there’s no automatic link. This creates blind spots. A dangerous reaction seen in Brazil might be missed if the U.S. system doesn’t pick it up - and vice versa.
WHO’s strength isn’t speed - it’s scope. With data from 170+ countries, it catches regional risks others miss. For example, the Dengvaxia dengue vaccine was found to increase severe dengue in people who’d never had the disease before - a risk first flagged by reports from the Philippines. That signal wouldn’t have been visible in Europe or North America alone.
Why Some Systems Work Better Than Others
It’s not just about technology. It’s about resources. The WHO Global Benchmarking Tool shows that only 42% of low- and middle-income countries have pharmacovigilance systems that meet minimum standards. Many lack trained staff, funding, or even internet access. In Africa, pharmacovigilance budgets average just $0.02 per person. In the U.S., it’s over $1.20.
Training is another issue. WHO recommends 40 hours of specialized training for pharmacovigilance officers. In Southeast Asia, 68% of officers got less than 15 hours. Without proper training, reports are incomplete or misclassified. A symptom like "dizziness" might be coded as "headache," hiding a pattern.
But there are success stories. Ethiopia cut its reporting time from 90 days to 14 after adopting PViMS, a web tool developed by MTaPS. It didn’t fix everything - only 35% of health facilities still report regularly due to poor connectivity - but it proved change is possible.
The Role of AI and New Tech
Manual review can’t keep up with 35 million reports. That’s why AI is stepping in. UMC’s AI-assisted signal detection system, rolled out in 2023, cut false positives by 28%. Instead of sifting through noise, analysts now focus on the most likely dangers.
Another breakthrough is electronic vaccine monitoring. Since 2020, 45 low- and middle-income countries have adopted digital tools for tracking vaccine side effects. In places like Kenya and Indonesia, data that used to take 60 days to reach global centers now arrives in 7. This is critical for vaccines - where timing matters more than ever.
Looking ahead, the ISO IDMP (Identification of Medicinal Products) standard, launching in 2025, will standardize how drugs are named and tracked across 100+ data points. That could improve cross-border matching by 40%, making it easier to spot global patterns.
What’s Next?
Drug safety monitoring is growing. The global pharmacovigilance market hit $5.38 billion in 2022 and is on track to hit $13.17 billion by 2030. Big pharma now spends heavily on safety teams - the top 50 companies average 250 full-time pharmacovigilance staff each.
But the system still has cracks. Only 62% of countries have even basic systems. And 32% of low-income systems rely on donor funding, which can vanish overnight. Without sustainable investment, the world’s most vulnerable populations will continue to be invisible in the data.
The goal isn’t just to collect reports. It’s to act on them - quickly, fairly, and globally. A drug that causes liver damage in one country might be safe elsewhere. But if we don’t see the pattern, we can’t protect anyone.
What is pharmacovigilance?
Pharmacovigilance is the science and activities focused on detecting, understanding, and preventing adverse effects from medicines. It’s not just about recording side effects - it’s about turning those reports into actions that improve patient safety and public health.
How does VigiBase work?
VigiBase is the WHO’s global database for adverse drug reaction reports. It collects standardized electronic reports (ICSRs) from over 170 countries. Each report is coded using WHODrug Global for drug names and MedDRA for symptoms. Advanced software scans the data for unusual patterns, or "signals," that suggest a medicine might be causing unexpected harm.
Why are reports from rich countries so much higher?
High-income countries have better infrastructure: trained staff, digital reporting tools, public awareness campaigns, and funding. In Sweden, over 1,200 adverse events are reported per 100,000 people each year. In Nigeria, it’s 2.3. The difference isn’t safety - it’s reporting capacity. Many low-income countries lack even basic systems to collect or transmit data.
Is the WHO system better than the EU or US systems?
It’s not better - it’s different. The EU system is faster and legally enforceable. The U.S. system gets more reports. But WHO’s strength is global coverage. It catches regional risks others miss, like the dengue vaccine issue in Southeast Asia. No single system is perfect. They work best when they share data.
Can patients report adverse reactions themselves?
Yes - in many countries, patients can report directly. The UK’s Yellow Card app lets anyone submit a report in under a minute. In Australia, the TGA accepts patient reports online. While healthcare professionals still submit most reports, patient input is growing. A patient noticing a new rash after taking a drug could be the first clue to a serious safety issue.
What’s being done to fix reporting gaps in poor countries?
Programs like MTaPS are helping by providing free web-based tools like PViMS, which work on low-bandwidth networks. WHO is training local officers and helping countries build national databases. Mobile reporting apps and SMS-based systems are being tested in remote areas. The goal is to make reporting as simple as sending a text message - even without internet.
How do regulators act on these reports?
When a signal is confirmed, regulators can issue warnings, update drug labels, restrict use, or even withdraw a medicine. For example, after VigiBase flagged a link between a diabetes drug and pancreatitis, the FDA updated its warning label. In the EU, PRAC can recommend a suspension within weeks. The system doesn’t just collect data - it triggers real-world safety actions.
Are all adverse reactions reported?
No. Studies estimate that fewer than 10% of serious adverse reactions are reported globally. Many go unnoticed because patients don’t connect them to a drug, or doctors assume they’re normal. That’s why systems are shifting toward active surveillance - using electronic health records to automatically flag possible reactions, not just waiting for reports.